ASTH vs MYGN: fair value comparison
Astrana Health, Inc. and Myriad Genetics, Inc. · Updated 2026-10-19
MYGN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MYGN currently ranks higher by quality score.
| ASTH | MYGN | |
|---|---|---|
| Verdict | Undervalued | No estimate yet |
| Last price | $36.81 | $3.98 |
| 12-month range | $18.16–$49.81 | $2.86–$8.18 |
| Rank by discount to fair value | #99 of 108 Healthcare | — |
| Rank by quality score | #202 of 301 Healthcare | #201 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | High | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: ASTH fair value analysis · MYGN fair value analysis